ADV-TK Improves Outcome of Recurrent High-Grade Glioma

NCT00870181 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Malignant Glioma of Brain
Glioblastoma

Interventions

BIOLOGICAL: ADV-TK/GCV
PROCEDURE: Surgery
DRUG: systemic chemotherapy

Sponsor

Huazhong University of Science and Technology

Collaborators

[object Object]
[object Object]
[object Object]